Brokerages expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.12). Aurinia Pharmaceuticals reported earnings per share of ($0.19) in the same quarter last year, which suggests a positive year over year growth rate of 31.6%. The company is expected to report its next quarterly earnings report on Friday, November 3rd.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.05) to ($0.89). For the next year, analysts forecast that the company will report earnings of ($0.58) per share, with EPS estimates ranging from ($0.72) to ($0.43). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.10. The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%.

Several research firms have recently issued reports on AUPH. HC Wainwright lowered their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 18th. Vetr lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a report on Wednesday. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, August 15th. Finally, Cantor Fitzgerald set a $14.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $9.71.

Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.74 on Friday. The stock’s market capitalization is $562.69 million. The stock has a 50 day moving average price of $6.23 and a 200 day moving average price of $6.56. Aurinia Pharmaceuticals has a 52 week low of $1.97 and a 52 week high of $10.54.

A number of large investors have recently bought and sold shares of AUPH. Bank of New York Mellon Corp bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $595,000. TD Asset Management Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $241,000. Quantbot Technologies LP bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $275,000. NEA Management Company LLC grew its position in shares of Aurinia Pharmaceuticals by 18.2% during the 1st quarter. NEA Management Company LLC now owns 4,808,483 shares of the biotechnology company’s stock valued at $35,294,000 after acquiring an additional 740,740 shares during the period. Finally, Credit Agricole S A bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $1,393,000. 27.83% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/10/aurinia-pharmaceuticals-inc-auph-expected-to-announce-earnings-of-0-13-per-share.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.